Hiwatari N, Shimura S, Yamauchi K, Nara M, Hida W, Shirato K
First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Tohoku J Exp Med. 1997 Feb;181(2):285-95. doi: 10.1620/tjem.181.285.
Although both procollagen III aminopeptide (P-III-P) and transforming growth factor-beta (TGF-beta) are reported to be present in lung tissue and/or elevated in bronchoalveolar lavage fluid (BALF) from idiopathic pulmonary fibrosis (IPF) patients, we have little knowledge concerning the clinical significance of elevated P-III-P and TGF-beta levels in BALF. Using a radioimmunoassay, we measured P-III-P and TGF-beta in BALF from 48 IPF patients (16F and 32M, 59 +/- 2 years, mean +/- S.E.) who received BAL in our clinic over the past 13 years before glucocorticosteroid treatment. Among them, we could detect a significant amount of P-III-P (2.2 +/- 1.0 U/ml; range 0.03 to 16.5 U/ml) in BALF in 18 of the patients (5F and 13M, 58 +/- 3 years) (group B). but not (0.03 U/ml or less) in the other 30 patients (11F and 19M, 59 +/- 2 years) (group A). Lymphocyte (%) and basophil (%) in BALF from group B was much larger than that from group A (33% vs. 8%, p < 0.01). Group B showed a longer duration of onset to BAL (36 months vs. 23 months, p < 0.05). TGF-beta levels were obtained using an ELISA system kit from the same BALF samples. TGF-beta was not detected in 10 patients (100 pg/ml or less) (3F and 7M, 59 +/- 4 years) (group I), while the remaining 38 patients showed a significant amount of TGF-beta (329 +/- 44 pg/ml, range 100 to 1,360 pg/ml). The latter patients were further divided into two groups; group II 100 to 300 pg/ml (10F and 14M, 56 +/- 3 years) and group III 350 or more (3F and 11M, 63 +/- 2 years). Group III showed significantly better values in PaO2, Aa-DO2, %VC and %DLco, and smaller percentage of basophils in BALF than did groups I and/or II, whereas survival after BAL in group III was significantly shorter than in group I (31 vs. 19 months, p < 0.05). There was no significant relationship between P-III-P and TGF-beta levels in BALF. These findings suggest that elevated P-III-P level is accompanied by an increase in lymphocyte population in BALF from IPF patients, resulting in a longer duration of the disease, while elevated TGF-beta level reflects alveolar inflammation at an earlier stage of the disease which induces a progression of the disease, resulting in a shorter survival in IPF patients.
虽然据报道,前胶原III氨基肽(P-III-P)和转化生长因子-β(TGF-β)都存在于肺组织中,和/或在特发性肺纤维化(IPF)患者的支气管肺泡灌洗液(BALF)中升高,但我们对BALF中P-III-P和TGF-β水平升高的临床意义知之甚少。我们使用放射免疫分析法,检测了过去13年内在我们诊所接受BAL且未接受糖皮质激素治疗的48例IPF患者(16名女性和32名男性,平均年龄59±2岁,均值±标准误)BALF中的P-III-P和TGF-β。其中,18例患者(5名女性和13名男性,平均年龄58±3岁)(B组)的BALF中可检测到大量P-III-P(2.2±1.0 U/ml;范围0.03至16.5 U/ml),而其他30例患者(11名女性和19名男性,平均年龄59±2岁)(A组)中未检测到(0.03 U/ml或更低)。B组BALF中的淋巴细胞(%)和嗜碱性粒细胞(%)远高于A组(33%对8%,p<0.01)。B组从发病到进行BAL的时间更长(36个月对23个月,p<0.05)。使用ELISA系统试剂盒从相同的BALF样本中检测TGF-β水平。10例患者(3名女性和7名男性,平均年龄59±4岁)(I组)未检测到TGF-β(100 pg/ml或更低),而其余38例患者显示有大量TGF-β(329±44 pg/ml,范围100至1360 pg/ml)。后一组患者进一步分为两组;II组100至300 pg/ml(10名女性和14名男性,平均年龄56±3岁)和III组350 pg/ml及以上(3名女性和11名男性,平均年龄63±2岁)。III组在PaO2、Aa-DO2、%VC和%DLco方面的值明显优于I组和/或II组,且BALF中嗜碱性粒细胞的百分比更小,而III组BAL后的生存期明显短于I组(31个月对19个月,p<0.05)。BALF中P-III-P和TGF-β水平之间无显著关系。这些发现表明,IPF患者BALF中P-III-P水平升高伴随着淋巴细胞数量增加,导致病程延长,而TGF-β水平升高反映疾病早期的肺泡炎症,这会促使疾病进展,导致IPF患者生存期缩短。